<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394757</url>
  </required_header>
  <id_info>
    <org_study_id>P14193ONB</org_study_id>
    <secondary_id>2010-022772-31</secondary_id>
    <nct_id>NCT01394757</nct_id>
  </id_info>
  <brief_title>Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)</brief_title>
  <official_title>Brain Network Dysfunction as a Model for Schizophrenia: Connectivity Alterations Using Ketamine and Pharmacological Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alterations of functional brain networks have been frequently demonstrated in schizophrenia,&#xD;
      although the exact underlying molecular mechanisms remain unrevealed. Ketamine is known to&#xD;
      exert its schizophrenia-like effects through modulation of the glutamatergic system, thus&#xD;
      facilitating the investigation of the impact of this specific transmitter system on resting&#xD;
      state functional brain networks. The aim of the study is therefore to use pharmacological&#xD;
      functional Magnetic Resonance Imaging (phMRI) to examine changes in brain networks involved&#xD;
      in schizophrenia in response to ketamine application compared to placebo. 30 healthy subjects&#xD;
      (15 females) will be examined twice using a double-blind, placebo-controlled, randomized,&#xD;
      crossover, counterbalanced-order design. Resting state fMRI will be investigated before,&#xD;
      during and after either placebo or ketamine intravenous infusion for 20 minutes. Prior to the&#xD;
      main trial 10 additional participants will be included in an open pilot trial.&#xD;
&#xD;
      Hypothesis: Ketamine application will induce changes in resting state networks previously&#xD;
      associated with schizophrenia and in the connectivity of relevant brain regions such as the&#xD;
      striatum, thalamus, caudate, hippocampus and amygdala. Furthermore, the application of&#xD;
      ketamine will provoke changes in the BOLD-activation in three fMRI paradigms each performed&#xD;
      before and after ketamine infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ketamine-induced changes in BOLD-activity over time</measure>
    <time_frame>1 year</time_frame>
    <description>participants will be measured twice and all participants are expected to be recruited and measured within 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of task-induced BOLD-activity by ketamine application</measure>
    <time_frame>60 minutes (before and after ketamine infusion) at each MRI session (interval between MRI scans: 1 week)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine hydrochloride</intervention_name>
    <description>Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.</description>
    <other_name>Ketanest S</other_name>
    <other_name>Ketamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  general health based on history, physical examination, ECG, laboratory screening and&#xD;
             structured clinical interview for DSM-IV(SCID)&#xD;
&#xD;
          -  willingness and competence to sign the informed consent form&#xD;
&#xD;
          -  aged 18 to 55 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any medical, psychiatric or neurological illness&#xD;
&#xD;
          -  current or former substance abuse&#xD;
&#xD;
          -  any implant or stainless steel graft and any other contraindications for MRI&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  first degree relatives with a history of psychiatric illness or substance abuse&#xD;
&#xD;
          -  failures to comply with the study protocol or to follow the instructions of the&#xD;
             investigating team&#xD;
&#xD;
          -  lifetime use of antipsychotic drugs&#xD;
&#xD;
          -  treatment with psychotropic agents such as SSRIs within the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Lanzenberger, A/Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry and Psychotherapy, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.meduniwien.ac.at/neuroimaging/</url>
    <description>Homepage of the Functional Neuroimaging Group, Department of Psychiatry and Psychotherapy, Medical University of Vienna</description>
  </link>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>December 29, 2013</last_update_submitted>
  <last_update_submitted_qc>December 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Lanzenberger</investigator_full_name>
    <investigator_title>A/Prof. PD Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

